US2016145572A1PendingUtilityA1
Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes
Assignee: ASTERIAS BIOTHERAPEUTICS INCPriority: Jun 25, 2009Filed: Jul 5, 2015Published: May 26, 2016
Est. expiryJun 25, 2029(~3 yrs left)· nominal 20-yr term from priority
C12N 2502/23C12N 2506/02C12N 5/0623C12N 2502/09C12N 5/0622C12N 5/00C12Q 1/00C12N 5/0662C12N 5/0081C12N 5/0607C12Q 1/02C12N 5/0606C12N 13/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides methods for depleting extraneous phenotypes from a mixed population of cells comprising the in vitro differentiated progeny of primate pluripotent stem cells. The invention also provides mixed cell populations enriched for a target cell phenotype where the mixed cell population comprises the differentiated in vitro progeny of primate embryonic stem cells.
Claims
exact text as granted — not AI-modified1 - 18 . (canceled)
19 . A method of reducing the number of extraneous phenotypic cells in a mixed population of cells comprising oligodendrocyte progenitor cells that are the in vitro differentiated progeny of pPS cells and extraneous phenotypic cells expressing Cd49f, the method comprising:
a) contacting the mixed population of cells with one or more ligands that specifically bind to Cd49f; and b) separating the ligand-bound Cd49f expressing cells from the rest of the mixed population of cells, thereby reducing the number of extraneous phenotypic cells in the mixed population of cells.
20 . The method of claim 19 , wherein the ligand is an antibody.
21 . The method of claim 19 , wherein the ligand is bound to a solid support.
22 . The method of claim 21 , wherein the solid support is a bead.
23 . The method of claim 22 , wherein the bead is a magnetic bead.
24 . The method of claim 19 , wherein the extraneous phenotypic cells are epithelial lineage cells.
25 . The method of claim 19 , further comprising contacting the mixed population of cells with one or more ligands that specifically bind to EpCAM before step b).
26 . The method of claim 19 , further comprising contacting the mixed population of cells with one or more ligands that specifically bind to EpCAM after step b).
27 . A mixed population of cells enriched for oligodendrocyte progenitor cells, wherein the mixed population of cells comprises the in vitro differentiated progeny of pPS cells and wherein the mixed population has a reduced number of extraneous phenotypic cells expressing Cd49f.
28 . The mixed population of cells of claim 27 , wherein the extraneous phenotypic cells are epithelial lineage cells.
29 . The mixed population of cells of claim 27 , wherein the mixed population also has a reduced number of extraneous phenotypic cells expressing EpCAM.
30 . The mixed population of cells of claim 27 , wherein the mixed population also has a reduced number of extraneous phenotypic cells expressing a cytokeratin.
31 . A container comprising a composition comprising a population of oligodendrocyte progenitor cells depleted of extraneous phenotypic cells expressing Cd49f, wherein the oligodendrocyte progenitor cells and the extraneous phenotypic cells are the in vitro differentiated progeny of pPS cells.
32 . The container according to claim 31 , wherein the extraneous phenotypic cells are epithelial lineage cells.
33 . The container according to claim 31 , wherein the extraneous phenotypic cells further express EpCAM.
34 . The container according to claim 31 , wherein the extraneous phenotypic cells further express a cytokeratin.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.